Is AbbVie (ABBV) a Buy Right Now?
A plain-English read on AbbVie stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
AbbVie is currently priced at $246.04, reflecting a modest daily gain of 0.89%. The stock is trading above its 200-day average of $225.57, which is a common indicator used to determine if a stock is in an upward trend.
The RSI (Relative Strength Index)—a gauge of whether a stock has climbed too far, too fast—is at 45.1. This suggests the stock is in a neutral zone, neither overbought nor oversold, providing a stable foundation for the current buy signal.
Should you buy AbbVie stock?
The data supports a buy position as the price holds above its 200-day average. While the P/E ratio—a measure of price relative to earnings—is high at 103.8, the current trend suggests market strength. Always consider your own risk tolerance before entering a position.
Is ABBV a good stock for beginners?
AbbVie is a large company with a 52-week range between $190.75 and $267.47. Beginners should be aware that a P/E ratio of 103.8 indicates investors are paying a premium for current earnings, which can lead to price swings.
What's driving ABBV right now
The stock price is currently above its 200-day average of $225.57.
The stock has maintained a recent support level, or floor, at $241.2.
The P/E ratio of 103.8 suggests the stock is priced high relative to its earnings.
The stock faces resistance, or a ceiling, near its 52-week high of $267.47.
What AbbVie actually does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie by the numbers
Wall Street consensus on ABBV is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns AbbVie?
Institutions — pension funds, asset managers, index providers — hold 77.1% of ABBV, and the concentration matters: the largest single holder alone controls 8.53% of the company.
| Holder | Shares | % held |
|---|---|---|
| 150.70M | 8.53% | |
| 114.88M | 6.50% | |
| 81.22M | 4.60% |
Names withheld — plus 3 more records not shown.
See who owns itWhat AbbVie insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for AbbVie, none were an open-market buy or sell — they are awards, vesting, option exercises or derivative conversions, which is normal and says nothing about conviction either way. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading ABBV?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name ABBV — filed by 11 separate members or more and worth $53K–$445K combined (filings report bands, never exact amounts). 16 purchase-side, 9 sale-side, most recently on 2026-05-05.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2025-12-18 | SELL | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersWith the price holding above its 200-day average and sitting comfortably within its yearly range, the technical data points to a buy.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice ABBV risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about ABBV
Should I buy ABBV stock?+
The technical data shows the stock is in an upward trend above its 200-day average, which supports a buy signal.
Is ABBV a good long-term investment?+
While the stock is currently trending up, its high P/E ratio of 103.8 suggests you are paying a premium for those long-term earnings.
Is ABBV a buy or a sell?+
Based on the current price of $246.04 and its position above the 200-day average, the technical signal is a buy.
Is ABBV overvalued?+
With a P/E ratio of 103.8, the market is currently assigning a high valuation to the company's earnings.
Is ABBV a good stock for beginners?+
Beginners should note the 52-week range of $190.75 to $267.47, which shows the stock can move significantly over time.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold AbbVie (ABBV) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-07 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.